![]() |
市場調査レポート
商品コード
1433334
軟骨修復の世界市場:2023-2030年Global Cartilage Repair Market 2023-2030 |
||||||
カスタマイズ可能
|
軟骨修復の世界市場:2023-2030年 |
出版日: 2023年12月11日
発行: Orion Market Research
ページ情報: 英文 205 Pages
納期: 2~3営業日
|
世界の軟骨修復市場は予測期間(2023-2030年)にCAGR 5.2%で成長すると予測されます。市場成長の原動力は、変形性関節症などの骨・関節疾患の罹患率の増加と軟骨再生技術の進歩です。変形性関節症の有病率の増加は、老人人口の拡大、肥満やその他の関連要因の影響の高まりなどの要因に起因しています。WHOによると、2019年には世界中で約5億2,800万人が変形性関節症を患っており、1990年以来113%増加しています。変形性関節症患者の約73%は55歳以上の高齢者で、60%は女性です。有病率は3億6,500万人で、罹患する関節は膝が最も多く、次いで股関節、手の順です。
用途別では、膝関節のサブセグメントが世界の軟骨修復市場で大きなシェアを占めると予想されています。高齢化人口の増加、研究開発活動への投資、低侵襲手術への嗜好の高まり、交通事故やスポーツ関連の怪我の増加など、膝関節手術には様々な要因が起因しています。Arthroscopy, Sports Medicine, and Rehabilitationによると、構造的膝関節損傷はこの調査で21%の選手に発生し、全体の発生率は1,000試合露出あたり5.42人でした。年齢別に層別化すると、膝の構造的損傷の発生率は20歳未満の選手で最も高く(3.23/1000GE)、次いで30歳未満(3.11/1000GE)、25~29歳(2.97/1000GE)、20~24歳(2.26/100GE)の順でした。1試合あたりのプレー時間別では、30分以上(3.86/1000GE)の割合が最も高く、次いで20.0~29.9分(3.03/1000GE)、10.0~19.9分(1.82/1000GE)の順でした。
アジア太平洋地域は、治療率の上昇、薬価の高騰、先進医療技術、新興国のヘルスケアインフラの改善と相まって可処分所得の増加がアジア太平洋地域の軟骨修復市場を牽引していることから、予測期間中の成長が見込まれています。
すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予想されています。北米市場は、変形性関節症の罹患率の上昇、有利な政府のイニシアチブ、高度に発達したヘルスケアインフラなどの要因によって成長しています。米国疾病予防管理センターによると、2019~2021年の間に、米国成人の約5人に1人(21.2%)、約5,320万人が医師診断の関節炎を患っていました。関節炎は男性(16.3%)に比べ、女性(20.9%)に多いです。このように、変形性関節症の罹患率の増加は、軟骨修復・再生製品の需要を促進すると予想されます。
Global Cartilage Repair Market Size, Share & Trends Analysis Report by Types of Colorectal Cancer (Cell Based and Non-Cell Based), by Application Site (Ankle, Foot, Knee, and Hip), by Application (Hyaline Cartilage and Fibrocartilage), and by End-User (Hospitals and Ambulatory Surgical Centers), Forecast Period (2023-2030)
The global cartilage repair market is anticipated to grow at a CAGR of 5.2% during the forecast period (2023-2030). The market growth is driven by the increasing incidence of bone and joint disorders, such as osteoarthritis, as well as advancements in cartilage regeneration technology. The increasing prevalence of osteoarthritis is attributed to factors such as the expanding geriatric population and the rising impact of obesity and other related factors. According to the WHO, in 2019, about 528 million people around the globe were living with osteoarthritis, an increase of 113% since 1990. About 73% of people living with osteoarthritis are older than 55 years, and 60% are female. With a prevalence of 365 million, the knee is the most frequently affected joint, followed by the hip and the hand.
The global cartilage repair market is segmented on the modality, application site, application, and end-user. Based on the modality, the market is sub-segmented into cell based and non-cell based. Based on the application site, the market is sub-segmented into ankle, foot, knee, and hip. Based on the application, the market is sub-segmented into hyaline cartilage and fibrocartilage. Further, based on end user, the market is sub-segmented into hospitals and ambulatory surgical centers. Among the modality, the cell based sub-segment is anticipated to hold a considerable share of the market, owing to the growing preference for autologous chondrocyte transplants as a surgical treatment for damaged articular cartilage, including chondral and osteochondral lesions.
Among the application site, the Knee sub-segment is expected to hold a considerable share of the global cartilage repair market. Various factors are attributed to the knee surgery including the increasing ageing population, investments in research and development activities, the growing preference for minimally invasive procedures, rising road accidents and sports-related injuries. According to the Arthroscopy, Sports Medicine, and Rehabilitation, structural knee injuries occurred in 21% of players in this study with an overall rate of 5.42 injuries per 1,000 game exposures. Stratified by age, structural knee injury rate was greatest in players less than 20 years old (3.23/1000 GE) followed by less than 30 years old (3.11/1000 GE), 25 to 29 years (2.97/1000 GE), and 20 to 24 years (2.26/100 GE). Knee injury by minutes per game, the rate was greatest in those playing more than 30 minutes (3.86/1000 GE), followed by 20.0 to 29.9 minutes (3.03/1000 GE), and 10.0 to 19.9 minutes (1.82/1000 GE).
The global cartilage repair market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia pacific is anticipated to grow over the forecast year, owing to the rising treatment rates, inflated medicine prices, advanced medical technologies, the rising disposable income coupled with improving healthcare infrastructure in emerging economies are driving the cartilage repair market in the Asia Pacific.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The North America market is growing owing to factors including the rising incidence of osteoarthritis, favorable government initiatives and highly developed healthcare infrastructure. According to the Centers for Disease Control and Prevention, during 2019-2021, about 1 in 5 US adults (21.2%) or about 53.2 million people had doctor-diagnosed arthritis. Arthritis was more common among women (20.9%) compared to men (16.3%). Thus, the increasing incidence of osteoarthritis is expected to drive the demand for cartilage repair and regeneration products.
The major companies serving the cartilage repair market include Zimmer Biomet Holdings, Inc., Conmed Corp., Stryker Corp., Osiris Therapeutics, Inc., Smith & Nephew Plc, Arthrex, Inc, RTI Surgical, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2023, Marrow Access Technologies signed a distribution agreement with Spartan Medical. The distribution agreement offered patients in the Department of Veterans Affairs (VA) and Department of Defense (DoD) access to the SmartShot® Marrow Access Device, a new solution for using the body's own stem cells and healing capabilities to treat orthopedic soft tissue injuries of the shoulder, hip, knee, ankle, and foot.